On this page of StockholderLetter.com we present the latest annual shareholder letter from Citius Pharmaceuticals, Inc. — ticker symbol CTXR. Reading current and past CTXR letters to shareholders can bring important insights into the investment thesis.
2024 Annual Report
Included in the 2024 Annual Report:
Form 10-K filed with the U.S. Securities and Exchange Commission on
December 27, 2024 (excluding exhibits)
Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy.